Faes Farma, S.A. · BME:FAE

Faes Farma — Investor Presentation (April 2021)

37 slides from Faes Farma's investor presentation, Apr 12, 2021

  1. Slide 1: Faes Farma: A local business with a global footprint

    Faes Farma: A local business with a global footprint Capital Market Presentation Faes Farma 12th of April 2021

  2. Slide 2: Content

    Content 01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A 2

  3. Slide 3: A snapshot of our history

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A 3

  4. Slide 4: Almost 90 years in healthcare

    01 A snapshot of our history Faes Farma Almost 90 years in healthcare A snapshot of our history 1933 Faes Farma 1940-1949 1950-1979 1980-1989 1990-2009 2010-2021 today > 130 countries Foundation of Faes • Strenthening the • Expansion of the portfolio both Geographic footprint1 Farma in Lamiako, Spai

  5. Slide 5: Strengthening the core business, international expansion and diversification

    01 A snapshot of our history Strengthening the core business, international expansion and diversification Faes Farma´s strategy in the recent years 1 Strengthening the core 2 International expansion through 3 Diversification into new business partners and own subsidiaries businesses Restructuring th

  6. Slide 6: A success story of value creation

    01 A snapshot of our history A success story of value creation Revenue [2016 – 2020, M€] EBITDA [2016 – 2020, M€] Profit before tax [2016 – 2020, M€] +74% +108% +84% 411,5 107,1 84,9 236,9 46,1 51,5 2016 2020 2016 2020 2016 2020 6

  7. Slide 7: Successful track record of shareholder remuneration

    01 A snapshot of our history Succesful track record shareholders remuneration with returns superior to the pharmaceutical sector Share price Faes Farma, S&P 500 Pharma & Ibex 35 [Base 100] 240 220 200 Variance 180 Mar15-Mar21 160 Faes Farma + 56 % 140 S&P 500 Pharma + 30 % 120 100 - 27 % 80 IBEX 35

  8. Slide 8: 2020 Results

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A 8

  9. Slide 9: 2020 Final results: record figures in revenue, EBITDA and net profit

    02 2020 Results 2020 Final results: record figures in revenue, EBITDA and net profit Highlights: 2020 final results +7,4% 113M€ revenue Bilastine 411,5 • Revenue increase of 7,5M€ (+7%) versus 2019 383,2 Revenue • Strenghtened position of Bilastine in Japan: Market share gain over the full year 2020

  10. Slide 10: 2020 Growth was driven by our international businesses

    02 2020 Results 2020 Growth was driven by our international businesses Contribution to revenue growth per business area [2019 – 2020, M€] Animal and International LATAM & Iberia health Licenses export Nutrition 411,5 Existing 3,1 2,0 (1,2) subsidiaries BCN Medical 16,6 +7,4% 3,1 3,6 (3,0) 4,5 383,2

  11. Slide 11: Guidance 2021

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A 11

  12. Slide 12: Net profit to increase in 2021, compensating adverse external environment

    03 Guidance 2021 Net profit to increase in 2021, compensating the adverse impact from the external environment Perspective 2021 Accumulation of Bilastine stock at key partners Sales growth via expansion of Calcifediol and following the antihistaminic market reduction in 2020 Mesalazine licenses due

  13. Slide 13: Bilastine Licenses: the key adverse driver for 2021 expectations

    03 Guidance 2021 Bilastine Licenses: the key adverse driver 2021 expectations due to the conjunctural effect from Covid-19 in 2020 Bilastine sales of partners [M€] Evolution Bilanoa® in Japan [Sales vs LY, Yen] 297 258 259 Bilanoa is developing towards the + 10% 177 + 7% - 29% antihistamine branded

  14. Slide 14: Growth Strategy: Pharmaceutical business

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A A Pharmaceutical business B Animal Nutrition & Health C Future growth pillars 14

  15. Slide 15: Maximizing the value of the R&D portfolio through direct sales and international licenses

    04 Growth Strategy A Pharmaceutical Business Maximizing the value of the R&D portfolio through direct sales and international licenses Iberia Geographical Growth Areas LATAM & Export International Licenses Portfolio Bilastine Calcifediol Mesalazine Other R&D Growth projects Engines R&D 15

  16. Slide 16: Iberia: a consolidated business with growth potential

    04 Growth Strategy A Pharmaceutical Business | Iberia Iberia: a consolidated business, with an excellent branded image and future growth potential Iberia: Spain Total market evolution vs Faes Farma [Spain] Sales: own products vs. Licensed [2020, % value] 5,4% Market Faes Farma Licensed Market shares

  17. Slide 17: LATAM and Export: creating a strong commercial platform

    04 Growth Strategy A Pharmaceutical Business | LATAM and Export LATAM and Export: creating a strong commercial platform to bring new products to market LATAM and export Growth phases and current market situation Revenue expectations 2021 [2020-2021E, M€] •1 2008 – 2019: organic growth Organic sales

  18. Slide 18: International Licenses: a successful model based on 3 key molecules

    04 Growth Strategy A Pharmaceutical Business | International Licenses International Licenses: A successful model based on maximizing value on a global scale of 3 key molecules International Licenses 3 key products Bilastine Calcifediol Mesalazine Other molecules With a leading global Calcifediol in

  19. Slide 19: Why is Bilastine a blockbuster molecule in the antihistamine market?

    04 Growth Strategy A Pharmaceutical Business| Bilastine Why is Bilastine a blockbuster molecule in the antihistamine market? Sales of the main antihistamine molecules in markets Attributes of the Bilastine franchise where Bilastine is present [M€] • Projection of becoming the best-selling antihistam

  20. Slide 20: Building the largest portfolio of the most prescribed antihistamine

    04 Growth Strategy A Pharmaceutical Business| Bilastine Building the largest portfolio of the most prescribed antihistamine Antihistamine market sales per format [M€] Portfolio and pipeline of the Bilastina franchise # Year of first launch CAGR 2018-2020 AH + Decongestant Bilastine + Bilastine + 268

  21. Slide 21: What is the potential of the Bilastine franchise?

    04 Growth Strategy A Pharmaceutical Business| Bilastine What is the potential of the Bilastine franchise? Geographical coverage of Bilastine Market size 2.133 M€ Bilastine marketed Directly or via partners 554 M€ Bilastina licensed and pending launch with partners 139 M€ Other potential markets with

  22. Slide 22: Why is Calcifediol a star molecule on the market?

    04 Growth Strategy A Pharmaceutical Business| Calcifediol Why is Calcifediol a star molecule on the market? Global market1 sales of Vitamina per molecule [M€] Attributes of the Calcifediol franchise • Leading molecule in sales in Spain 1.200 CAGR • Patent for new formulation in main territories 2016

  23. Slide 23: Building a differential story for pro-hormone D

    04 Growth Strategy A Pharmaceutical Business| Calcifediol Building a differential story for pro-hormone D Portfolio and pipeline of the Calcifediol franchise # Year of first launch Pro-hormone D deficiency Bone health Medical Device Current formulations Gold standard Creating new treatment in market

  24. Slide 24: What is the potential of the Calcifediol franchise?

    04 Growth Strategy A Pharmaceutical Business| Calcifediol What is the potential of the Calcifediol franchise? Calcifediol geographic coverage Market size 319 M€ Calcifediol marketed Directly of via partners 505 M€ Calcifediol pending launch with partners1 26 M€ Calcifediol pending launch via subsidi

  25. Slide 25: Calcifediol treatment in Covid-19 patients

    04 Growth Strategy A Pharmaceutical Business| Calcifediol Calcifediol treatment in Covid-19 patients Pilot study of the effects of 3 indepentent medical studies in Immunocovidiol clinical trial treatment with Calcifediol versus patients hospitalized for Covid-19 promoted by Faes Farma untreated on I

  26. Slide 26: Why is Mesalazine a star molecule on the market?

    04 Growth Strategy A Pharmaceutical Business| Mesalazine Why is Mesalazine a star molecule on the market? Mesalazine sales by formulation1 [M€] Attributes of the Mesalazine franchise CAGR 2016-2020 • Market in continuous growth without new alternatives +1,2% 700 0,8 % • Recommended molecule in all g

  27. Slide 27: Building the largest portfolio of Mesalazine formulations

    04 Growth Strategy A Pharmaceutical Business| Mesalazine Building the largest portfolio of Mesalazine formulations Portfolio and pipeline of the Mesalazine franchise # Year of first launch + Tablets high dose 2025 Current formulations Amplified granule Potentially range + innovative disruptive techn

  28. Slide 28: What is the potential of the Mesalazine franchise?

    04 Growth Strategy A Pharmaceutical Business| Mesalazine What is the potential of the Mesalazina franchise? Geographic coverage of Mesalazina Market Size 216 M€ Mesalazina marketed Directly or via partners 383 M€ Mesalazina pending launch1 351 M€ Other potential markets with the entry strategy being

  29. Slide 29: Strengthening the portfolio in other drugs and therapeutic areas

    04 Growth Strategy A Pharmaceutical Business| Other R&D Projects Strengthening the Faes Farma portfolio in other drugs and therapeutic areas Portfolio and pipeline of other drugs Muscle Pain and Contractures Peripheral vascular Digestive + + Tablets high dose Tablet once a Rectal ointment + Potentia

  30. Slide 30: Industrial project: new manufacturing plant to deliver growth

    04 Growth Strategy A Pharmaceutical Business| Industrial Project Industrial project: new manufacturing plant to deliver the growth of the group New Plant in Derio, País Vasco, Production capacity need Production process improvement España from 2024 • Lamiako's production plant capacity is • Cost and

  31. Slide 31: Growth Strategy: Animal Nutrition & Health

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A A Pharmaceutical business B Animal Nutrition & Health C Future growth pillars 31

  32. Slide 32: Animal Nutrition & Health: leading player with high added value

    04 Growth Strategy B Animal Nutrition & Health Animal Nutrition & Health: Leading player in a segment with high added value and high profitability Animal Nutrition & Health Profitability superior to Growth prospects • Leader in early age swine nutrition the sector • Extensive R&D work: highly techno

  33. Slide 33: Future growth pillars

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A A Pharmaceutical business B Animal Nutrition & Health C Future growth pillars 33

  34. Slide 34: Future growth pillars

    04 Growth Strategy C Future growth pillars Future growth pillars A group with a mixed value proposition of its own and high-value licensed products, committed to 1 Products developing its portfolio based on a betting on R&D for the generation of new products and innovative solutions A consolidated i

  35. Slide 35: Closing / Q&A

    01 02 03 04 05 A snapshot of Closing / 2020 Results Guidance 2021 Growth Strategy our history Q&A

  36. Slide 36: Close and Q&A

    Close and Q&A Q&A dF FAES FARMA

  37. Slide 37: Disclaimer

    Disclaimer This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off

Faes Farma — Investor Presentation (April 2021) on 6ix